Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion type Assertion NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_head.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion description "[On August 2011, a small molecule inhibitor against ALK, crizotinib, was approved for therapy against NSCLC with ALK translocations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_provenance.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion evidence source_evidence_curated NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_provenance.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion SIO_000772 22968692 NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_provenance.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion wasDerivedFrom ctd_human-20130708 NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_provenance.
- NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_assertion wasGeneratedBy ECO_0000218 NP8460.RAGSVAzaKtwz66Qa3_b7tb9KJkpWtW29fnUnlos2xVsMw130_provenance.